The Alzheimer’s disease treatment market is projected to reach US$9.4 billion by 2027. Which stocks should be on investors’ radar?
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills.
According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.
Treatments are available to alleviate Alzheimer’s symptoms, but because they do not affect the underlying causes of the neurodegenerative disease, they’re only a bandaid solution.
Therapies approved by the US Food and Drug Administration include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine, now under AbbVie (NYSE:ABBV).
Although these and other treatments are available, there is no cure for Alzheimer’s, and death is often the result for patients as the disease devastates the brain.
And, unfortunately, Alzheimer’s disease is rising in prevalence. A report from Research and Markets suggests the global Alzheimer’s market will be worth US$9.4 billion by 2027 thanks to the rising need for drugs in development, along with investments made in biomarkers for further development.
Here the Investing News Network takes a look at a few of the biggest Alzheimer’s disease treatment stocks. Companies are listed in order of market cap from largest to smallest. All data for the Alzheimer’s disease treatment stocks on this list was current as of September 7, 2021.
1. Prothena (NASDAQ:PRTA)
Market cap: US$3.24 billion; current share price: US$71.89
The first Alzheimer’s disease treatment stock on this list is Prothena. This late-stage clinical company has developed a pipeline of novel therapeutics for the treatment of a number of neurodegenerative diseases, including Alzheimer’s disease, AL amyloidosis, ATTR amyloidosis and Parkinson’s disease.
In mid-2021, Prothena presented new data from its ongoing clinical studies of PRX005 for the treatment of Alzheimer’s disease. The company also received US$80 million from Bristol Myers Squibb (NYSE:BMY) for the exclusive US license to PRX005, with the option for worldwide rights following completion of an already initiated Phase 1 study. An investigational new drug application for PRX012 is expected to be filed by the company in the first quarter of 2022.
2. AC Immune (NASDAQ:ACIU)
Market cap: US$528.91 million; current share price: US$7.28
AC Immune’s overall focus is on developing treatments for neurodegenerative diseases such as Alzheimer’s. The company has two proprietary technology platforms: SupraAntigen and Morphomer. Within these platforms are eight Alzheimer’s disease treatments in different stages of clinical trials.
AC Immune’s lead Alzheimer’s drug candidate is crenezumab, an anti-Abeta antibody that is currently in a Phase 2 clinical trial for Alzheimer’s. The company recently released positive top-line data for another of its Alzheimer’s product candidates, semorinemab, which is also in Phase 2 studies.
3. Adamas Pharmaceuticals (NASDAQ:ADMS)
Market cap: US$209.28 million; current share price: US$4.59
Adamas Pharmaceuticals is focused on neurological conditions in patients with Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s.
The company’s Alzheimer’s dementia treatment, Namzaric, was developed in connection with Allergan and approved by the US Food and Drug Administration in 2014; Allergan was acquired by AbbVie in early 2020. Namzaric is a treatment taken once daily to treat moderate to severe Alzheimer’s and helps improve symptoms such as cognition and function impairment.
This is an updated version of an article first published by the Investing News Network in 2019.
Don’t forget to follow @INN_LifeScience for real-time updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.